Tocagen says Toca 5 Phase 3 clinical trial continues without modification
Tocagen last night announced that the Toca 5 Phase 3 clinical trial evaluating Toca 511 and Toca FC in patients with recurrent high grade glioma continues without modification following a planned interim analysis of data conducted by an Independent Data Monitoring Committee. The IDMC completed its analysis and recommended the trial continue without modification, the company said in a statement. The global trial enrolled patients across two periods of time and completed full enrollment of 403 patients in November 2018. "We are encouraged by the recommendation from the IDMC to continue the Toca 5 trial without modification and are looking forward to reporting the final analysis of the Toca 5 trial by the end of the year," said Marty Duvall, CEO of Tocagen. "We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints." Shares of Tocagen are down 27%, or $2.37, to $6.45 in premarket trading.